Rakovina Therapeutics Upsizes Financing to $2M

Rakovina Therapeutics Inc., a biopharmaceutical company, announced an upsized financing of up to approximately $2 million. This financing includes a previously announced non-brokered private placement of an unsecured convertible debenture and two million common share purchase warrants, totaling $1.0 million. Concurrently, the company proposes a common share private placement of up to 8,333,334 common shares at $0.12 per share, aiming for an additional $1.0 million. The proceeds are intended to support near-term working capital for ongoing corporate activities and strategic initiatives. The closing of these private placements is contingent on obtaining necessary corporate and regulatory approvals, including from the TSX Venture Exchange.